Description
“Mass-Action Law Dynamics Theory and Algorithm for Translational and Precision Medicine Informatics provides a comprehensive overview and update of the mass-action law-based unified dose-effect biodynamics, pharmacodynamics, bioinformatics, and the combination index theorem for synergy definition (MAL-BD/PD/BI/CI). Contents advocate the fundamental MAL-PD/BI/CI/BI principle for biomedical R&D, clinical trials protocol design computerized data analysis, illustrates the MAL-dynamics theory with sample analysis, and includes data entry and automated computer report print-outs. In 11 sections “Mass-Action Law Dynamics Theory and Algorithm for Translational and Precision Medicine Informatics leads the reader from an introduction and overview, to trial protocols and MAL-PD/CI approach for biomedical R&D in vitro and in animals. It describes the current Landscape of International FDA Drug Evaluation, Clinical Pharmacology, and Clinical Trials Guidance. This is a valuable resource for biomedical researchers, healthcare professionals, and students seeking to harness the power of data informatics in precision medicine.
• gives insight into that index equation (DRIE) that digitally determines how many folds of dose-reduction is needed for each drug in synergistic combinations • provides a comprehensive overview and update of mass-action law-based unified bioinformatics, dose effect biodynamics, pharmacodynamics, and the combination index theorem for synergy definition (MAL-BD/PD/BI/CI) • describes how the MAL theory/algorithm-based “Top-Down digital approach is the opposite and yet is a complementary alternative to the observation/statistics-based “Bottom-Up traditional approach in R&D
Table of Contents
1. A new alternative concept for cost-effective R&D: The MALdynamics/algorithms/digital informatics
2. General dynamics principle for experimental design of all dose-effect analysis and computer simulation
3. MAL-PD/CI approach for biomedical R&D in vitro and in animals
4. Implementation for MAL-PD Econo-Green R&D
5. Digital R&D approach to international FDA drug evaluation, clinical pharmacology, and clinical trial guidance
6. The epothilone story: Experimental success and clinical failure
7. MAL-PD Advocacy: Public hearing, public comments and scientific recommendations
8. Consensus for international FDAs on definitions of “MAL-PD” and “Synergism”
9. Historical, philosophical, and mathematical analysis: Why the MAL-PD approach and the traditional approach are opposite yet complementary
10. Multidisciplinary examples of applications: Papers using the MAL-PD/BD/CI/BI theory/method
11. Concluding remarks
